Isturisa bulk pharmacy
Ended Awarded Last action
- Contract number
- 36C26025F0034
- Awardee
-
Recordati Rare Diseases Inc. UEI LL38YHW3Y9P4
- Awarding agency
-
Veterans Integrated Service Network 20
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $672,259
Award facts
- Contract value 100% obligated
- $672,259.47 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Bartlett, TN 38134, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$15,769 | |
| Funding Only Action | $402,238 | |
| Original award | $285,791 |
About this award
The Department of Veterans Affairs, Veterans Integrated Service Network 20 (VISN 20), awarded a delivery order valued at $672,259.47 to Recordati Rare Diseases Inc. on December 15, 2024, for the supply of Isturisa (osilodrostat) bulk pharmacy products with an ultimate completion date of December 14, 2025. This firm fixed-price delivery order, which carries no set-aside designation, is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and represents an increase in usage and pricing for this critical orphan pharmaceutical product. Recordati Rare Diseases Inc., a foreign-owned pharmaceutical manufacturer headquartered in Bridgewater, New Jersey, with distribution operations in Bartlett, Tennessee, serves as the prime contractor with no identified subcontractors involved in this award.
This delivery order is issued under one of two existing indefinite-delivery vehicles that Recordati maintains with the VA: a $15.6 million multiple-award Federal Supply Schedule contract awarded in April 2021 and a $3.16 million single-award Blanket Purchase Agreement established in July 2021. Both parent contracts provide the VA with streamlined procurement authority to access Recordati's specialized rare disease pharmaceutical portfolio, including treatments for Cushing's syndrome, acromegaly, hyperammonemia, and other uncommon endocrine and metabolic disorders. These contract vehicles reflect the VA's recognition of Recordati's critical role as a specialized supplier of orphan drugs with limited competitive availability, ensuring reliable access to essential medications for veteran populations across multiple service networks.
Quick answers
Who was awarded contract 36C26025F0034?
36C26025F0034 was awarded to Recordati Rare Diseases Inc. by Veterans Integrated Service Network 20 (Veterans Health Administration) on December 15, 2024.
How much is contract 36C26025F0034 worth?
The government has obligated $672,259 on 36C26025F0034.
Is contract 36C26025F0034 an order under another contract?
Yes. 36C26025F0034 is a delivery order under 36F79721D0141, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26025F0034 competed?
The extent of competition for 36C26025F0034 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award